Boron-containing carbonic anhydrases inhibitors

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Drug Discovery

Background:

• Boron-based compounds have shown therapeutic potential for cancer, infections, and neurological disorders.
• Carbonic anhydrases (CAs) are key drug targets with significant medicinal chemistry relevance.
• Boron incorporation into inhibitors can enhance target recognition and isoform selectivity for CAs.

Purpose of the Study:

• To review the current advancements in boron-based carbonic anhydrase inhibitors (CAIs).
• To highlight the unique properties of boron in designing novel CAIs.
• To discuss the potential of boron-based CAIs in medicinal chemistry and future clinical applications.

Main Methods:

• Review of existing literature on boron-based compounds and CAIs.
• Analysis of boron's role in modulating ligand-target interactions and selectivity.
• Exploration of boron-containing zinc-binding inhibitors, including boronic acids and benzoxaboroles.

Main Results:

• Boron-based CAIs offer unique mechanisms for inhibiting carbonic anhydrases.
• Boronic acids and benzoxaboroles represent novel classes of zinc-binding CAIs.
• The electron-deficient nature of boron facilitates Lewis acid-base interactions with CA active sites.

Conclusions:

• Boron-based CAIs are a rapidly developing area in medicinal chemistry.
• Further investigation is crucial to realize the full therapeutic potential of these compounds.
• Advancing boron-based CAIs towards clinical applications requires continued research and development.